Stereotactic radiotherapy for oligometastases in the lymph nodes

Francesco Pasqualetti¹, Fabio Trippa², Cynthia Aristei³, Simona Borghesi⁴, Caterina Colosimo⁵, Martina Cantarella⁶, Rosario Mazzola⁷, Gianluca Ingrosso⁸

¹Department of Radiation Oncology, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Italy
²Radiation Oncology Centre, S. Maria Hospital, Terni, Italy
³Radiation Oncology Section, University of Perugia and Perugia General Hospital, Italy
⁴Radiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, Italy
⁵Operative Unit of Radiotherapy, Department of Oncology, San Luca Hospital, Lucca, Italy
⁶Radiation Oncology, Casa di Cura San Rossore, Pisa, Italy
⁷Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy

ABSTRACT

Even though systemic therapy is standard treatment for lymph node metastases, metastasis-directed stereotactic radiotherapy (SRT) seems to be a valid option in oligometastatic patients with a low disease burden. Positron emission tomography-computed tomography (PET-CT) is the gold standard for assessing metastases to the lymph nodes; co-registration of PET-CT images and planning CT images are the basis for gross tumor volume (GTV) delineation. Appropriate techniques are needed to overcome target motion. SRT schedules depend on the irradiation site, target volume and dose constraints to the organs at risk (OARs) of toxicity. Although several fractionation schemes were reported, total doses of 48–60 Gy in 4–8 fractions were proposed for mediastinal lymph node SRT, with the spinal cord, esophagus, heart and proximal bronchial tree being the dose limiting OARs. Total doses ranged from 30 to 45 Gy, with daily fractions of 7–12 Gy for abdominal lymph nodes, with dose limiting OARs being the liver, kidneys, bowel and bladder. SRT on lymph node metastases is safe; late side effects, particularly severe, are rare.

Key words: stereotactic radiotherapy; radiosurgery; oligometastasis; lymph node metastases; organ motion; hypofractionation; BED; local control; toxicity

Rep Pract Oncol Radiother 2022;27(1):46–51

Introduction

Even though systemic therapy is standard treatment for lymph node metastases from solid tumors, metastasis-directed stereotactic radiotherapy (SRT) seems to be a valid option [1–4] in oligometastatic patients with a low disease burden [5]. New imaging tools [6, 7] and biomarkers [8] have improved the definition of disease extension and can indicate whether the metastasis is suitable for ablative SRT, thus potentially obviating the need for regional prophylaxis with nodal irradiation and postponing systemic therapy.

The rationale for SRT relies on the hypothesis that metastatic deposits promote disease spread and that their eradication could potentially be curative [9]. Several mainly retrospective analyses demonstrated that SRT delayed disease progression in
patients with oligometastatic lymph node disease [2, 10]. Others reported on its efficacy in terms of local control (LC) and progression-free survival (PFS) in patients with node metastases from different primary tumors [11–15]. Eventually, ablative SRT as a progression-directed therapy might be integrated with systemic SOC therapy in the oligoprogressive setting, in order to ablate resistant clonogens delaying progression and time to the switch to a new systemic line of treatment [16–20]. Although there are still few randomized prospective trials, a phase II trial with a screening design (the SABR-COMET) was the first to demonstrate that in oligometastatic patients with ≤ 5 metastases SRT combined with standard of care (SOC) impacted more positively on OS than SOC alone (41 vs. 28 months; p = 0.090) [1]. More recently, the ORIOLE phase 2 randomized clinical trial reported that SRT significantly improved disease progression at 6 months in comparison with observation in prostate cancer patients with oligometastatic disease to the bones and lymph nodes (19% vs. 61%, p = 0.005). Median progression free survival, not reached after SRT, was 5.8 months in the observation group (p = 0.002) [21].

The present-day challenge is to assess whether SRT actually changes prognosis in patients with oligometastatic lymph node disease.

### Diagnostic imaging and target volume definition

Diagnostic imaging plays a crucial role in detecting the earliest stages of metastatic deposits and in defining oligometastatic disease. More specifically, molecular imaging tools reliably detected distant lesions that conventional imaging such as computed tomography (CT) missed [22–25]. Many studies investigated the use of positron emission tomography (PET) with different tracers in oligo-metastatic and oligo-recurrent settings, especially in prostate cancer patients [26, 27]. For instance, the European Association of Urology (EAU) guidelines strongly recommended prostate specific membrane antigen (PSMA)-PET in patients with biochemical recurrence after primary treatment for localized prostate cancer [28].

Co-registration of PET [29, 30] and planning 2.5-3 mm slice CT images are the basis for GTV delineation. A four-dimensional CT (4DCT) or repeated planning CTs are used to define the internal target volume (ITV), thus overcoming the target motion issue. There is no uniform consensus about ITV margins that provide the planning target volume (PTV). They depend on the metastasis site (e.g., abdomen, thorax, head and neck), immobilization system, treatment planning system, image-guided technique and the fractionation scheme. Image-guidance is mandatory in dose delivery.

### Fractionation schedules and dose constraints to the OARs

SRT schedules depend on the irradiation site, target volume and dose constraints to the organs at risk (OARs) of toxicity which have to be in accordance with the recommendations of the AAPM Task Group 101 [31]. Moreover, a consensus on normal tissue dose constraints for SRT has recently been published [32]. Although several fractionation schemes were reported, total doses of 48–60 Gy in 4–8 fractions were proposed for the treatment of mediastinal lymph nodes [33–35] with the spinal cord, esophagus, heart and proximal bronchial tree being the dose limiting OARs. Total doses ranged from 30 to 45 Gy, with daily fractions of 7–12 Gy [30, 36] for abdominal lymph nodes, with dose limiting OARs being the liver, kidneys, bowel and bladder (Tab. 1).

The SABR-COMET-10 phase III trial is going to investigate the role of stereotactic ablative radiotherapy in oligometastatic (< 10 lesions) disease. Recommended doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions [37]. In a recent systematic review on stereotactic ablative radiotherapy for lymph node metastases from solid tumors, it has been reported a pooled 2-year local control of 79.3% (95% CI: 72.8–85.7%) [38].

### Toxicity

SRT on lymph node metastases is safe, with toxicity rates ranging from 0% to 15% [2–4, 13, 27, 30]. Risk factors for acute and late toxicities include, as expected, the irradiation site, target volume and dose to the OARs. Acute grade ≥ 2 toxicity (mainly mucositis) was reported in about 5% of patients [30]. Late toxicity, which occurs from 3 to 6 months after SRT, is reported to be rare. In fact, under 5% of
patients experienced late grade ≥ 2 toxicity; severe complications are rare, with the thorax being the most challenging site showing a grade ≥ 3 toxicity of 2.0% [13, 30, 38].

**Discussion**

SRT is currently used in daily clinical practice for the treatment of lymph node oligometastatic disease, although the majority of the results rely on retrospective series with inhomogeneity in terms of patient characteristics, of imaging tools for baseline oligometastatic assessment and follow-up, of treatment planning and delivery techniques [11, 13, 26-27, 33, 36, 43-48]. More specifically, reported outcomes (e.g. LC, PFS) are based on different imaging modalities with different diagnostic sensitivity. Another issue is that at diagnosis many patients being treated with ablative therapy for oligometastatic node disease actually have undetected microscopic disease. Several authors have questioned about the opportunity to treat these patients with extended-field radiotherapy instead of SRT. Local ablative treatment might be a wise option because it has been demonstrated that patients affected by oligometastatic disease limited to lymph nodes will experience mainly nodal oligoprogression rather than widespread disease [39], giving the possibility of a repeated SRT strategy. On the other hand, there are several experiences in literature about the combination of prophylactic regional nodal irradiation and ablative boost to the nodal lesion. For instance, in pelvic oligorecurrent prostate cancer Rischke et al. [40] demonstrated that prophylactic nodal irradiation added to salvage lymph node dissection results in a significant delay of node relapse within the treated region compared with surgery only (5-yr relapse-free rate 70.7% vs. 26.3%, p < 0.0001). Even though prophylactic irradiation on lymph node chains is effective, it is associated with grade ≥ 2 toxicity rates ranging from 15% to 25% [41, 42]. Eventually, to date, no comparative studies between SRT vs extended field irradiation have been published.

Concerning toxicity of SRT for lymph node metastases, low rates ranging from 0% to 15% have been reported [11, 13, 26-27, 33, 36, 43-48]. The retrospective nature of available data, with different inclusion criteria, limit the comparability of toxicity rates in the analyzed studies.

**Table 1. Studies on stereotactic radiotherapy (SRT) for patients affected by oligometastatic disease limited to lymph nodes**

| Autor [year] | Dose/fractions |
|--------------|----------------|
| Macchia et al. [2020] [33] | Median dose 25 Gy/median fractions 3 |
| Ost et al. [2018] [36] | 30 Gy/3 |
| Jereczek-Fossa et al. [2017] [45] | Median dose 24 Gy/3 (range 15–36 Gy/3) |
| Ingrosso et al. [2017] [43] | 12–50 Gy/1–5 |
| Franzese et al. [2017] [44] | 45 Gy/6 |
| Ost et al. [2016] [27] | 24–30 Gy/3, 25–30 Gy/5, 50 Gy/10 |
| Franceschini et al. [2016] [13] | 30–60 Gy/5–8 |
| Pasqualetti et al. [2016] [26] | 24 Gy/1, 27 Gy/3 |
| Meng et al. [2015] [47] | Median dose 8 Gy (range 3–8 Gy)/ median fractions 5 (range 3–15) |
| Detti et al. [2015] [46] | 24 Gy/1, 27–36 Gy/3, 30 Gy/5 |
| Park et al. [2015] [11] | 13 Gy/3 |
| Bignardi et al. [2011] [48] | 45 Gy/6 |

**Conclusions**

Although currently supported by a weak level of evidence, SRT in patients affected by oligometastatic disease limited to lymph nodes reduces disease burden, and delays clinical progression. Recently published results from SABR-COMET trial [1] and from ORIOLE trial [21] strengthen the role of this treatment modality in the oligometastatic setting. In the near future, advances in molecular imaging as well as in molecular biology and genetics will help to better define the true oligometastatic state leading to a molecular stratification of different prognostic classes. Eventually, SRT will be the treatment of choice in selected patients, whereas in other cases it will be used in treatment intensification strategies.

**Conflicts of interest**

The authors have no conflict of interest to declare.
Funding
This publication was prepared without any external source of funding.

Ethical permission
Ethical approval was not necessary for the preparation of this article.

References
1. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051–2058, doi: 10.1016/S0140-6736(18)32487-5, indexed in Pubmed: 30986867.
2. Lancia A, Zilli T, Achard V, et al. Oligometastatic prostate cancer: The game is afoot. Cancer Treat Rev. 2019; 73: 84–90, doi: 10.1016/j.ctrv.2019.01.005, indexed in Pubmed: 30684842.
3. Tree AC, Khoov VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013; 14(1): e28–e37, doi: 10.1016/S1470-2045(12)70510-7, indexed in Pubmed: 23276369.
4. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic ablative body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012; 118(11): 2962–2970, doi: 10.1002/cncr.26611, indexed in Pubmed: 22020702.
5. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10, doi: 10.1200/JCO.1995.13.1.8, indexed in Pubmed: 7799047.
6. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020; 77(4): 403–417, doi: 10.1016/j.eururo.2019.01.049, indexed in Pubmed: 30773328.
7. Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group (EORTC LCG). EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019; 122: 109–114, doi: 10.1016/j.ejca.2019.09.012, indexed in Pubmed: 31671363.
8. Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastases (es). PLoS One. 2011; 6(12): e28650, doi: 10.1371/journal.pone.0028650, indexed in Pubmed: 22174856.
9. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016; 352(6282): 169–175, doi: 10.1126/science.aaf2784, indexed in Pubmed: 27124450.
10. Trovo M, Furlan C, Polese J, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol. 2018; 126(1): 177–180, doi: 10.1016/j.radonc.2017.08.032, indexed in Pubmed: 28943046.
11. Park HJ, Chang AR, Seo Y, et al. Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a cooperative study of the Korean Radiation Oncology Group (KROG 1411). Anticancer Res. 2015; 35: 5103–5110, indexed in Pubmed: 26254414.
12. Iyengar P, Timmerman RD. Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes. J Natl Compr Canc Netw. 2012; 10(12): 1514–1520, doi: 10.6094/jnccn.2012.0157, indexed in Pubmed: 23221789.
13. Franceschini D, De Rose F, Fogliata A, et al. Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget. 2016; 7(33): 53321–53329, doi: 10.18632/oncotarget.10826, indexed in Pubmed: 27462869.
14. De Rose F, Cozzi L, Navarria P, et al. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clin Oncol (R Coll Radiol). 2016; 28(1): 13–20, doi: 10.1016/j.clon.2015.08.011, indexed in Pubmed: 26385822.
15. Quan K, Xu KM, Zhang Y, et al. Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma. Semin Radiat Oncol. 2016; 26(2): 112–119, doi: 10.1016/j.semradiol.2015.11.007, indexed in Pubmed: 27000507.
16. Berghen C, Joniau S, Ost P, et al. Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. Eur Urol Oncol. 2021; 4(2): 305–309, doi: 10.1016/j.euo.2019.08.012, indexed in Pubmed: 31558422.
17. Valeriani M, Marinelli L, Macrini S, et al. Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enalutamide treatment: a mono-institutional experience. Radiat Oncol. 2019; 14(1): 205, doi: 10.1186/s13014-019-1414-x, indexed in Pubmed: 31727093.
18. Moyer CL, Phillips R, Deek MP, et al. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol. 2019; 37(12): 2623–2629, doi: 10.1007/s00345-018-2477-2, indexed in Pubmed: 30191396.
19. Deek MP, Taparra K, Phillips R, et al. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. Eur Urol Oncol. 2021; 4(3): 447–455, doi: 10.1016/j.euo.2020.05.004, indexed in Pubmed: 32536574.
20. Ingrosso G, Detti B, Fodor A, et al. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol. 2021; 23(8): 1577–1584, doi: 10.1007/s12994-021-02553-5, indexed in Pubmed: 33495981.
21. Phillips R, Shi YW, Deek M, et al. Observations vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5): 650–659, doi: 10.1001/jamaoncol.2020.0147, indexed in Pubmed: 32215577.
22. Liu B, Gao S, Li S. A Comprehensive Comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer: A Meta-Analysis Based on 67
Studies. Gynecol Obstet Invest. 2017; 82(3): 209–222, doi: 10.1159/000456006, indexed in Pubmed: 28183074.

23. Fantl S, Minozzi S, Castellucci P, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016; 43(1): 55–69, doi: 10.1007/s00259-015-3202-7, indexed in Pubmed: 26450693.

24. Morigli JJ, Stricker PD, van Leeuwen PJ, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56(8): 1185–1190, doi: 10.2967/jnumed.115.160382, indexed in Pubmed: 26112024.

25. Ichpujani VK, Rao SA, Chaturvedi AK, et al. Positron emission tomography-computed tomography: a superior and one-stop shop modality for treated head and neck carcinoma compared with conventional tomography. J Oral Maxillofac Surg. 2014; 72(11): 2319–2332, doi: 10.1016/j.joms.2014.06.419, indexed in Pubmed: 25438279.

26. Pasqualetti F, Panichi M, Sainato A, et al. (18)F-Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016; 11: 9, doi: 10.1186/s13014-016-0586-x, indexed in Pubmed: 26796633.

27. Ost P, Jereczek-Fossa BA, van As N, et al. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (R Coll Radiol). 2016; 28(9): e115–e120, doi: 10.1016/j.clon.2016.04.040, indexed in Pubmed: 27133946.

28. Prostate cancer. http://uroweborg/guideline/prostate-cancer/ (13 January 2020.).

29. De Cuyper M, Lovinfosse P, Goffin F, et al. Added value of para-aortic surgical staging compared to F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. Eur J Surg Oncol. 2020; 46(5): 883–887, doi: 10.1016/j.ejso.2019.11.496, indexed in Pubmed: 31784203.

30. Ponti E, Lancia A, Ost P, et al. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. Eur Urol Focus. 2017; 3(6): 538–544, doi: 10.1016/j.euf.2017.07.006, indexed in Pubmed: 28801240.

31. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37(8): 4078–4101, doi: 10.1118/1.3438081, indexed in Pubmed: 20879569.

32. Hanna GG, McDonald F, Murray L, et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2018; 30(1): 5–14, doi: 10.1016/j.clon.2017.09.007, indexed in Pubmed: 29033164.

33. Macchia G, Lazzari R, Colombo N, et al. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist. 2020; 25(2): e311–e320, doi: 10.1634/theoncologist.2019-0309, indexed in Pubmed: 32043791.

34. De Ruyscher D, Faire-Finn C, Moeller D, et al. Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC). European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017; 124(1): 1–10, doi: 10.1016/j.radonc.2017.06.003, indexed in Pubmed: 28666551.

35. Schneider B, Daly M, Kennedy E, et al. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2018; 36(7): 710–719, doi: 10.1200/jco.2017.74.9671, indexed in Pubmed: 29257717.

36. Spaas M, Sundahl N, Hulstae A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018; 36(5): 446–453, doi: 10.1200/JCO.2017.75.4853, indexed in Pubmed: 29240541.

37. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19(1): 816, doi: 10.1186/s12885-019-5977-6, indexed in Pubmed: 31426760.

38. Deodato F, Macchia G, Buwenge M, et al. Systematic review of stereotactic body radiotherapy for nodal metastases. Clin Exp Metastasis. 2021; 38(1): 11–29, doi: 10.1007/s10585-020-10071-x, indexed in Pubmed: 33452954.

39. Ost P, Jereczek-Fossa BA, Van As N, et al. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (R Coll Radiol). 2016; 28(9): e115–e120, doi: 10.1016/j.clon.2016.04.040, indexed in Pubmed: 27133946.

40. Rischke HC, Schultz-Seemann W, Wieser G, et al. Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol. 2015; 191(4): 310–320, doi: 10.1007/s00066-014-0763-5, indexed in Pubmed: 25326142.

41. Fodor A, Berardi G, Fiorino C, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU Int. 2017; 119(3): 406–413, doi: 10.1111/bju.13510, indexed in Pubmed: 27104782.

42. Würschmidt F, Petersen C, Wahl A, et al. [18F]fluorocholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011; 6: 44, doi: 10.1186/1748-717X-6-44, indexed in Pubmed: 21529377.

43. Ingrosso G, Trippa F, Maranzano E, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017; 35(1): 45–49, doi: 10.1007/s00034-016-1861-x, indexed in Pubmed: 29240541.

44. Franzese C, Lopeci E, Di Brina L, et al. 11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. Cancer Invest. 2017; 35(9): 586–593, doi: 10.1080/07359707.2017.1375116, indexed in Pubmed: 28980836.
45. Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clin Genitourin Cancer. 2017; 15(4): e623–e632, doi: 10.1016/j.clgc.2017.01.004, indexed in Pubmed: 28185875.

46. Detti B, Bonomo P, Masi L, et al. Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World J Urol. 2015; 33(8): 1197–1203, doi: 10.1007/s00345-014-1427-x, indexed in Pubmed: 25342516.

47. Meng MB, Wang HH, Zaorsky NG, et al. Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget. 2015; 6(17): 15690–15703, doi: 10.18632/oncotarget.3704, indexed in Pubmed: 25881546.

48. Bignardi M, Navarria P, Mancosu P, et al. Clinical Outcome of Hypofractionated Stereotactic Radiotherapy for Abdominal Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2011; 81(3): 831–838, doi: 10.1016/j.ijrobp.2010.05.032, indexed in Pubmed: 20800375.